Related Experiment Videos
New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma
1Virginia Piper Cancer Institute, Minneapolis, Minnesota 55407.
Abstract:
Several important new agents are effecting the management of non-Hodgkin lymphoma (NHL) and multiple myeloma. The two selected for review in this article include a biologic-response modifier and a new chemotherapeutic agent. The biologic-response modifiers offer entirely new approaches to these diseases. The most extensively tested agent currently has been recombinant alpha-interferon (alpha-IFN). The IFN are active, albeit weak, remission-induction agents for low-grade NHL and some T-cell lymphomas, but they appear to be ineffective as single agents in most intermediate-grade or high-grade NHL and myeloma. However, an emerging pattern in follicular lymphomas and myeloma is that alpha-IFN in combination with chemotherapy may lead to more complete and durable clinical responses and the increased prospect of prolonged disease control. Fludarabine, a new chemotherapeutic agent, is a promising drug with demonstrated activity in low-grade lymphomas that parallels its impressive activity in chronic lymphocytic leukemia.
Insights
New biologic agents and chemotherapy show promise for non-Hodgkin lymphoma (NHL) and multiple myeloma. Recombinant alpha-interferon (alpha-IFN) combined with chemotherapy may improve responses in follicular lymphomas and myeloma.
Area of Science:
- Oncology
- Hematology
Background:
- Non-Hodgkin lymphoma (NHL) and multiple myeloma are hematologic malignancies with evolving treatment landscapes.
- Biologic-response modifiers and novel chemotherapeutic agents represent new therapeutic avenues.
Purpose of the Study:
- To review the efficacy of recombinant alpha-interferon (alpha-IFN) and fludarabine in managing NHL and multiple myeloma.
- To explore the potential of these agents, both as monotherapies and in combination regimens.
Main Methods:
- Review of current literature on alpha-IFN and fludarabine in hematologic malignancies.
- Analysis of clinical data regarding response rates, durability, and disease control.
Main Results:
- Alpha-IFN demonstrates weak remission-induction activity in low-grade NHL and some T-cell lymphomas but is largely ineffective as a single agent in higher-grade NHL and myeloma.
- Combination therapy with alpha-IFN and chemotherapy shows potential for more complete and durable responses in follicular lymphomas and myeloma.
- Fludarabine exhibits promising activity in low-grade lymphomas, comparable to its efficacy in chronic lymphocytic leukemia.
Conclusions:
- Biologic-response modifiers like alpha-IFN offer novel approaches to NHL and multiple myeloma.
- Combination strategies involving alpha-IFN and chemotherapy may enhance clinical outcomes and prolong disease control.
- Fludarabine is a valuable new chemotherapeutic agent for specific lymphoma subtypes.